PL363081A1 - Growth hormone secretagogues - Google Patents

Growth hormone secretagogues

Info

Publication number
PL363081A1
PL363081A1 PL01363081A PL36308101A PL363081A1 PL 363081 A1 PL363081 A1 PL 363081A1 PL 01363081 A PL01363081 A PL 01363081A PL 36308101 A PL36308101 A PL 36308101A PL 363081 A1 PL363081 A1 PL 363081A1
Authority
PL
Poland
Prior art keywords
growth hormone
hormone secretagogues
growth
secretion deficiency
hormone secretion
Prior art date
Application number
PL01363081A
Other languages
Polish (pl)
Other versions
PL216676B1 (en
Inventor
Jean Martinez
Jean-Alain Fehrentz
Vincent Guerlavais
Original Assignee
Zentaris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Ag filed Critical Zentaris Ag
Publication of PL363081A1 publication Critical patent/PL363081A1/en
Publication of PL216676B1 publication Critical patent/PL216676B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0212—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -N-C-N-C(=0)-, e.g. retro-inverso peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

The invention relates to compounds of formula I which are useful for elevating the plasma level of growth hormone in a mammal as well as for the treatment of growth hormone secretion deficiency, growth retardation in child and metabolic disorders associated with growth hormone secretion deficiency.
PL363081A 2000-06-13 2001-06-13 Growth hormone secretagogues PL216676B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21132600P 2000-06-13 2000-06-13
US23492800P 2000-09-26 2000-09-26
PCT/EP2001/006717 WO2001096300A1 (en) 2000-06-13 2001-06-13 Growth hormone secretagogues

Publications (2)

Publication Number Publication Date
PL363081A1 true PL363081A1 (en) 2004-11-15
PL216676B1 PL216676B1 (en) 2014-05-30

Family

ID=26906052

Family Applications (1)

Application Number Title Priority Date Filing Date
PL363081A PL216676B1 (en) 2000-06-13 2001-06-13 Growth hormone secretagogues

Country Status (29)

Country Link
US (2) US6861409B2 (en)
EP (1) EP1289951B1 (en)
JP (2) JP3522265B2 (en)
KR (1) KR100825109B1 (en)
CN (1) CN1232507C (en)
AR (1) AR029941A1 (en)
AT (3) ATE370119T1 (en)
AU (2) AU6606601A (en)
BG (3) BG66130B1 (en)
BR (1) BRPI0111591B8 (en)
CA (1) CA2407659C (en)
CY (2) CY1107710T1 (en)
CZ (2) CZ303173B6 (en)
DE (3) DE60112753T2 (en)
DK (3) DK1344773T3 (en)
ES (3) ES2288724T3 (en)
FR (1) FR19C1044I2 (en)
HU (1) HU229233B1 (en)
IL (2) IL153067A0 (en)
MX (1) MXPA02011899A (en)
NL (1) NL300999I2 (en)
NO (1) NO323873B1 (en)
NZ (1) NZ522280A (en)
PL (1) PL216676B1 (en)
PT (2) PT1524272E (en)
RU (1) RU2270198C2 (en)
SK (1) SK287169B6 (en)
TW (2) TW200831076A (en)
WO (1) WO2001096300A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR029941A1 (en) * 2000-06-13 2003-07-23 Zentaris Gmbh USEFUL COMPOUNDS TO ELEVATE THE PLASMATIC LEVEL OF GROWTH HORMONE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CU23157A1 (en) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TISSULAR DANE DUE TO LACK OF BLOOD IRRIGATION ARTERIAL
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US7034050B2 (en) * 2004-04-28 2006-04-25 Romano Deghenghi Pseudopeptides growth hormone secretagogues
US8138218B2 (en) * 2005-07-22 2012-03-20 Ipsen Pharma S.A.S. Growth hormone secretagogues
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
GB0603295D0 (en) * 2006-02-18 2006-03-29 Ardana Bioscience Ltd Methods and kits
CU23558A1 (en) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE
US7763707B2 (en) * 2006-03-13 2010-07-27 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation
KR20090107088A (en) 2007-02-09 2009-10-12 트랜자임 파르마 인크 Macrocyclic ghrelin receptor modulators and methods of using the same
EP2103602A1 (en) 2008-03-17 2009-09-23 AEterna Zentaris GmbH Novel 1,2,4-triazole derivatives and process of manufacturing thereof
US8431642B2 (en) * 2008-06-09 2013-04-30 Exxonmobil Chemical Patents Inc. Polyolefin adhesive compositions and articles made therefrom
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
US9198889B2 (en) 2012-09-19 2015-12-01 Quality IP Holdings, LLC Methods for treating post-traumatic stress disorder
US8747921B2 (en) 2012-09-19 2014-06-10 Quality Ip Holdings, Inc. Methods for improving health in humans
US8747922B2 (en) 2012-09-19 2014-06-10 Quality Ip Holdings, Inc. Methods and compositions for increasing sex steroids and growth hormones
US10300101B2 (en) 2012-09-19 2019-05-28 Quality IP Holdings, LLC Methods and compositions for enhancing or maintaining fertility
US10292957B2 (en) 2012-09-20 2019-05-21 Quality IP Holdings, LLC Compositions and methods for treating fibromyalgia
US8715752B2 (en) 2012-09-20 2014-05-06 Quality Ip Holdings, Inc. Compositions for increasing human growth hormone levels
US9066953B2 (en) 2012-09-20 2015-06-30 Quality IP Holdings, LLC Methods for increasing endurance and fat metabolism in humans
US8747923B2 (en) 2012-09-20 2014-06-10 Quality Ip Holdings, Inc. Methods for improving health in canines
WO2014065341A1 (en) 2012-10-24 2014-05-01 第一三共株式会社 Therapeutic agent for amyotrophic lateral sclerosis
CN105330720A (en) * 2014-06-06 2016-02-17 深圳翰宇药业股份有限公司 Method for preparing macimorelin
HUE057831T2 (en) * 2015-09-21 2022-06-28 Lumos Pharma Inc Recognition and treatment of growth hormone deficiency
US10894072B2 (en) 2017-02-13 2021-01-19 IP Quality Holdings, LLC Compositions and methods for treating fibromyalgia
US10288629B1 (en) 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
CN120294343A (en) 2020-07-22 2025-07-11 阿特纳赞塔里斯有限公司 A screening method for diagnosing growth hormone deficiency in pediatric patients by using macirelin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880778A (en) * 1986-05-12 1989-11-14 Eastman Kodak Company Combinations having synergistic growth hormone releasing activity and methods for use thereof
DE68922602T2 (en) * 1988-01-28 1995-12-07 Polygen Holding Corp POLYPEPTIDES WITH A HORMONE GROWTH RELEASING EFFECT.
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
CA2176140A1 (en) * 1993-11-24 1995-06-01 Meng Hsin Chen Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US6025471A (en) * 1998-06-03 2000-02-15 Deghenghi; Romano Diazaspiro, azepino and azabicyclo therapeutic peptides
AR029941A1 (en) * 2000-06-13 2003-07-23 Zentaris Gmbh USEFUL COMPOUNDS TO ELEVATE THE PLASMATIC LEVEL OF GROWTH HORMONE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Also Published As

Publication number Publication date
US20020165343A1 (en) 2002-11-07
HUP0302026A3 (en) 2009-01-28
US7297681B2 (en) 2007-11-20
NO20025893L (en) 2003-02-10
CY1107710T1 (en) 2013-04-18
NZ522280A (en) 2004-09-24
BG66217B1 (en) 2012-05-31
ES2288724T3 (en) 2008-01-16
CN1232507C (en) 2005-12-21
JP2004503536A (en) 2004-02-05
CZ20024095A3 (en) 2003-05-14
DE60112753T2 (en) 2006-06-29
BG110771A (en) 2011-03-31
KR100825109B1 (en) 2008-04-25
BG107379A (en) 2003-09-30
FR19C1044I1 (en) 2019-09-08
SK287169B6 (en) 2010-02-08
DE60128494D1 (en) 2007-06-28
NL300999I2 (en) 2019-08-28
AR029941A1 (en) 2003-07-23
JP3522265B2 (en) 2004-04-26
US20040229823A1 (en) 2004-11-18
CA2407659C (en) 2010-11-09
DK1524272T3 (en) 2007-09-03
DE60112753D1 (en) 2005-09-22
PL216676B1 (en) 2014-05-30
ATE302181T1 (en) 2005-09-15
JP2003335752A (en) 2003-11-28
ATE370119T1 (en) 2007-09-15
BG66216B1 (en) 2012-05-31
PT1524272E (en) 2007-07-25
DK1344773T3 (en) 2007-12-27
BG110708A (en) 2010-12-30
EP1289951B1 (en) 2005-08-17
HU229233B1 (en) 2013-09-30
TWI305529B (en) 2009-01-21
PT1344773E (en) 2007-11-27
DE60130025D1 (en) 2007-09-27
AU2001266066B2 (en) 2005-06-30
BR0111591A (en) 2003-05-06
WO2001096300A1 (en) 2001-12-20
RU2270198C2 (en) 2006-02-20
KR20030007889A (en) 2003-01-23
BR0111591B1 (en) 2014-02-04
DE60130025T2 (en) 2008-05-15
HUP0302026A2 (en) 2003-09-29
FR19C1044I2 (en) 2020-07-24
IL153067A0 (en) 2003-06-24
TW200831076A (en) 2008-08-01
CN1431998A (en) 2003-07-23
CA2407659A1 (en) 2001-12-20
BG66130B1 (en) 2011-06-30
CZ305279B6 (en) 2015-07-15
NO323873B1 (en) 2007-07-16
SK17562002A3 (en) 2003-05-02
AU6606601A (en) 2001-12-24
CZ303173B6 (en) 2012-05-16
HK1054224A1 (en) 2003-11-21
IL153067A (en) 2010-05-31
US6861409B2 (en) 2005-03-01
JP4932132B2 (en) 2012-05-16
CY1107793T1 (en) 2013-06-19
ES2250416T3 (en) 2006-04-16
ATE362472T1 (en) 2007-06-15
NO20025893D0 (en) 2002-12-09
DK1289951T3 (en) 2005-12-19
ES2292900T3 (en) 2008-03-16
MXPA02011899A (en) 2003-04-22
BRPI0111591B8 (en) 2021-05-25
EP1289951A1 (en) 2003-03-12
NL300999I1 (en) 2019-07-17
DE60128494T2 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
PL363081A1 (en) Growth hormone secretagogues
UA92355C2 (en) urn:schemas-microsoft-com:office:smarttags2,4-DIAMINO-PYRIMIDINES USED AS AURORAINHIBITORS
MXPA02012203A (en) Glucagon-like peptide-1 analogs.
MY135841A (en) Novel benzodioxoles
MY126527A (en) Novel dihydropyrimidines
YU65502A (en) Substituted beta-carbolines with ikb-kinase inhibiting activity
EG24358A (en) Isoindolin-1-one glucokinase avtivators
BG106003A (en) New n-cyanomethylamides and compositions as protease inhibitors
MXPA03007837A (en) Compositions for delivering bisphosphonates.
DE602004011394D1 (en) Thiazolderivate
GB0003025D0 (en) Novel compounds
HU9902668D0 (en) Compounds with growth hormone releasing properties
MY141020A (en) Novel pparalpha and ppargamma agonists
GB0018951D0 (en) Novel compounds
IL135825A0 (en) Use of mirtazapine for treating sleep apneas
MXPA05014184A (en) Use of hyaluronic acid for preparing compositions for treating oral cavity aphthas.
PL365165A1 (en) Tricyclic imidazopyridines
GB0326633D0 (en) Therapeutic agents
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
GB0027705D0 (en) Novel compounds
NZ515531A (en) Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
DK1100824T3 (en) Compounds with growth hormone releasing properties
MY136138A (en) Hexacyclic compounds
YU30602A (en) Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischeamic conditions
NO20012169D0 (en) Compounds with growth hormone releasing properties